What Is Ketamine Therapy? A Complete Medical Guide

In the autumn of 1999, a small research team at Yale gave seven patients with treatment-resistant depression a single sub-anesthetic dose of intravenous ketamine and watched the depression lift within hours, a timeline that contradicted everything psychiatry understood about antidepressant mechanisms. The paper that followed, published in Biological Psychiatry in February 2000, was ignored for about a decade. Today it is recognized as the most important antidepressant discovery since the introduction of imipramine in the 1950s, and the clinical field that has grown from it is reshaping how psychiatry thinks about treatment-resistant depression, suicidal ideation, PTSD, and chronic pain. Ketamine itself is not new (it has been used as an anesthetic since 1962 and appears on the WHO's List of Essential Medicines) but its psychiatric application is, and the clinical literature supporting it has matured rapidly since the mid-2010s. This guide covers the pharmacology, mechanism, indications, safety profile, and dosing detail that healthcare professionals and informed patients should understand.

The Pharmacology, and Why It Matters Clinically

Ketamine is an arylcyclohexylamine (IUPAC name 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; formula C₁₃H₁₆ClNO, molecular weight 237.7 g/mol), and it exists as two mirror-image forms that behave differently in the body. The S(+) enantiomer, esketamine, is the more potent NMDA blocker and is the molecule the FDA approved as Spravato. The R(-) enantiomer, arketamine, is less psychoactive and, in preclinical work, appears to produce longer-lasting effects. The racemic mixture, equal parts of both, is what most off-label psychiatric practice uses, including the compounded sublingual formulations we prescribe for at-home treatment.

What makes ketamine interesting clinically is not any one of those facts but the mechanism they add up to. Ketamine is a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor. It binds inside the channel and blocks glutamate's action there, and it does so in a voltage- and use-dependent way, meaning it blocks more aggressively where neurons are firing hardest. That selectivity for the most active circuits is part of why a sub-anesthetic dose can shift mood without shutting down the whole brain.

The antidepressant effect, though, is downstream of that initial blockade. Blocking NMDA receptors triggers a cascade: a rebound surge of glutamate activates AMPA receptors, which switches on the mTOR signaling pathway, drives release of brain-derived neurotrophic factor (BDNF), and promotes the growth of new dendritic spines, the physical connection points between neurons. Ketamine also modulates HCN1 channels. The practical translation is that ketamine appears to rebuild synaptic connections that chronic depression and stress erode, and it starts doing so within hours, which is the mechanistic reason the clinical effect arrives so much faster than an SSRI's.

Why glutamate, when every other antidepressant targets serotonin

For sixty years the dominant model of depression was the monoamine hypothesis: too little serotonin or norepinephrine, corrected by drugs that raise those levels. That model gave us useful medications, but its limits are the reason ketamine matters. SSRIs and SNRIs produce a response in only about 30 to 40 percent of patients, take four to six weeks to work, carry high relapse rates, and leave a large group with treatment-resistant illness.

The glutamate hypothesis reframes the problem. In this view the pathology sits in the brain's primary excitatory system: chronic stress and neuroinflammation drive dysregulated glutamate signaling and tip the glutamate-GABA balance, and the downstream cost is a loss of synaptic connectivity in the prefrontal cortex and hippocampus, the regions most tied to mood and cognition. Ketamine intervenes directly in that system. It briefly dampens the excess glutamate signaling, provokes the compensatory AMPA-and-neuroplasticity cascade described above, and, in responders, produces measurable antidepressant effects within hours to days rather than weeks. It is not a better serotonin drug; it works on a different axis entirely, which is exactly why it reaches patients the serotonin drugs cannot.

What Ketamine Therapy Treats, and How Well

Only one ketamine-based product carries an FDA psychiatric approval. Esketamine (Spravato), approved in 2019, is indicated for treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior. It is a nasal spray, administered in a certified setting under a REMS (Risk Evaluation and Mitigation Strategy) program with a mandatory observation period. Everything else in psychiatric ketamine practice, including the racemic sublingual and IV protocols, is off-label: legal, evidence-supported prescribing of an approved drug for an unapproved indication, the same footing as a great deal of routine psychiatry. The off-label indications with the most clinical use are generalized anxiety disorder, PTSD, OCD, bipolar depression, and chronic pain syndromes including complex regional pain syndrome.

Treatment-resistant depression is the flagship indication and the one with the strongest data. The working definition is failure to respond to at least two adequate antidepressant trials, where "adequate" means a therapeutic dose sustained for at least six weeks, preferably from different pharmacological classes. By that standard, 10 to 30 percent of people with major depression are treatment-resistant. In this population the numbers ketamine posts are unusual: response rates of 60 to 70 percent in clinical trials, full remission in 30 to 40 percent, improvement typically within 24 to 72 hours, and an effect from a single session that lasts on the order of one to two weeks, which is what drives the multi-session induction schedule.

Suicidal ideation is where the speed is most consequential. Ketamine can reduce suicidal thinking within two to four hours, a window in which no oral antidepressant does anything at all, with the benefit sustained for one to two weeks. The proposed mechanisms are of a piece with the rest: rapid mood stabilization that blunts impulsivity, improved cognitive flexibility, and the restoration of some hope through fast symptom relief, all supported by the underlying neuroplastic effect. For a patient in acute crisis, that rapid if temporary reduction in risk is a genuinely different kind of tool, and it is one of the clearest arguments for the drug's place in psychiatry.

How It's Given: Routes, Doses, and Trade-offs

The four routes in real use differ mainly in bioavailability, onset, and where they can safely be done.

Intravenous ketamine is the most-studied route and the one with the tightest dosing control. The standard psychiatric protocol is 0.5 mg/kg infused over about 40 minutes, given two to three times a week during the induction phase and then spaced to every one to two weeks for maintenance, with most practices holding below 1.0 mg/kg per session. Onset is fast, roughly 5 to 10 minutes, and the infusion can be slowed or stopped in real time, which is why IV is preferred for the highest-acuity patients. The cost is that it requires a clinical setting, IV access, staff time, and the higher price that comes with all three.

Sublingual ketamine is the route built for at-home care and the one we use most. A typical starting dose is 200 to 300 mg held under the tongue, titrated up by about 100 mg based on response, with most patients settling into a 300 to 800 mg range and established protocols going as high as 1000 mg (1 g) per session. The trade-off is pharmacokinetic: sublingual bioavailability is only about 25 to 30 percent, and absorption varies between people, so the dosing is less precise than IV and the taste takes some getting used to. In exchange you get a gentler onset curve that most patients tolerate better at home, no need for IV access, and a fraction of the cost.

Intramuscular ketamine, dosed around 1 to 2 mg/kg with onset in 5 to 15 minutes and effects lasting one to two hours, is used mainly in settings where IV access is impractical: emergencies, patients who can't take oral medication, and some research and anesthesia contexts. It gives up the moment-to-moment control of IV, because once it's injected it can't be dialed back.

Intranasal esketamine (Spravato) follows a fixed, FDA-defined schedule: 56 mg or 84 mg twice weekly for the first four weeks of induction, then weekly or every-other-week maintenance. It must be given in a healthcare facility with a two-hour post-dose observation period, which is the operational tax that comes with its insurance-covered status.

Who Is a Candidate, and Who Isn't

The honest version of candidacy is a clinical judgment, not a checklist, so let me describe it the way I actually think about it in an evaluation.

The patients who benefit most are the ones the rest of psychiatry has struggled to reach: treatment-resistant depression after two or more adequate medication trials, depression severe enough to impair daily function, acute suicidal ideation that needs a faster intervention than an SSRI can offer, bipolar depression that hasn't responded to mood stabilizers, and PTSD with a heavy symptom burden. Beyond the diagnosis, the practical predictors of a good course are unglamorous: a patient who is motivated and engaged, who can reliably make appointments, who has someone at home to support them through the treatment, and who comes in with realistic expectations rather than expecting a single dose to erase years of illness. Ketamine works best as part of a plan the patient is committed to, not as a rescue they passively receive.

Some patients should not receive ketamine, or not yet. The absolute contraindications are mostly cardiovascular and neurologic, because ketamine reliably raises blood pressure and heart rate: uncontrolled hypertension (above roughly 180/110 mmHg), a myocardial infarction within the last three months, unstable angina or other severe cardiac disease, severe aortic stenosis, and raised intracranial pressure. Active psychosis or schizophrenia is the key psychiatric exclusion, since a dissociative drug can worsen it. Then there are the relative contraindications, where the drug isn't off the table but the risk-benefit calculation gets careful: poorly controlled hypertension (above about 160/100), active substance use disorder, pregnancy (where safety simply isn't established), severe liver disease that complicates metabolism, and any history of ketamine misuse.

Sorting a patient into the right category is the job of a real workup, not a questionnaire. Before a first dose I want a cardiovascular screen with an ECG and baseline blood pressure, a full psychiatric history, an honest substance-use history, a medication review for interactions, basic labs including a metabolic panel and liver function, and a baseline read on cognition. Skipping that evaluation is how avoidable complications happen.

What Actually Happens During and After a Session

For a patient who is a good candidate, the acute experience is well characterized and, handled properly, unremarkable.

The dissociative effects are the part people ask about most. They begin 5 to 15 minutes after dosing and last one to two hours: a sense of being disconnected from the body, distorted time, sometimes mild perceptual changes. Managed in a calm environment with reassurance and monitoring, this is a feature of the treatment rather than a complication, and it resolves as the drug clears. The cardiovascular effects are the ones that actually warrant monitoring: blood pressure typically rises 20 to 30 percent and heart rate 10 to 20 percent during the dose, returning to baseline within two to four hours, which is exactly why the contraindication list leans cardiac and why vitals are watched continuously during treatment and periodically afterward. Other common short-lived effects are nausea or vomiting in 10 to 20 percent of patients, dizziness and unsteadiness, blurred or double vision, and temporary mild cognitive fog.

The longer-term safety picture, at therapeutic doses, is reassuring but not something to be casual about. Physical dependence is rare with clinical dosing, though tolerance can develop with frequent use, and the addiction potential in a supervised clinical population is low, which is not license to ignore use patterns. Cognition is generally preserved or actually improves as the depression lifts, memory effects are minimal at appropriate doses, and executive function often gets better as the underlying illness recedes. The urological concern that gets attention, ketamine-associated bladder toxicity, is genuinely rare at clinical doses and is overwhelmingly a problem of high-dose, chronic recreational use; the sensible practice is adequate hydration, appropriate dosing, and a urinalysis if urinary symptoms appear.

The Arc of Response

Response to ketamine unfolds on a predictable timeline, and setting that expectation is part of the treatment. In the first four hours, the dissociative and cardiovascular effects peak and resolve and cognition returns to baseline, and some patients notice the first lift in mood before they even leave. Over the first one to three days, the more meaningful mood improvement tends to consolidate, often with better sleep, reduced suicidal thinking, and steadier emotion. Across the following one to two weeks, responders hold those gains and start re-engaging with work and relationships, which is the window a single session buys and the reason sessions are spaced the way they are. The maintenance phase that follows is about finding the individual dosing interval that sustains remission, which for many patients means gradually stretching the time between sessions and, sometimes, reducing reliance on other medications.

Not everyone responds, and it's worth being candid about who tends to. The features associated with a better response are younger age (generally under 65), a shorter duration of the current episode, and, in some studies, lower baseline severity and prior psychedelic experience; treatment engagement itself, which correlates loosely with things like education, matters because this is a treatment you participate in. The features that predict a harder course are active substance use, severe personality pathology, multiple medical comorbidities, thin social support, and a history of not adhering to treatment. None of these is an absolute bar. They're the factors I weigh when I tell a patient honestly how likely this is to help them specifically.

Ketamine Works Best Inside a Larger Plan

Ketamine is a catalyst, not a standalone cure, and the practices that get the best results treat it that way. The neuroplastic window it opens is an opportunity for change that therapy can consolidate. Pairing treatment with structured psychotherapy (cognitive-behavioral therapy, dialectical behavior therapy, acceptance and commitment therapy, trauma-focused approaches for PTSD, interpersonal therapy for relational patterns) tends to make the gains last. The timing matters as much as the school: preparation and expectation-setting before the session, minimal intrusion during the acute effects themselves, real integration work afterward to process what came up, and steady effort between sessions to hold the therapeutic progress.

Medications need coordination too. Existing antidepressants are usually continued through a ketamine course unless there's a specific reason to stop. A few interactions are worth knowing: benzodiazepines may blunt ketamine's antidepressant effect, and lamotrigine has been associated with reduced response, while most antipsychotics are compatible. Any tapering of other medications should be gradual, monitored during the transition, and driven by the individual patient's response and preference rather than a fixed protocol. Around all of this, the ordinary levers still apply: a consistent sleep schedule with limited caffeine and alcohol, regular physical activity, an anti-inflammatory diet with adequate omega-3 intake, and stress-management or mindfulness practice all support the same neuroplastic recovery the drug initiates.

What It Takes to Deliver This Safely

Ketamine therapy is not a treatment to offer casually, and the standard of care is specific. A clinician needs a working command of ketamine's pharmacology and mechanism, genuine competence in psychiatric assessment and diagnosis, the ability to evaluate cardiovascular risk, emergency-management protocols for the rare event that a session goes sideways, and clear patient-selection criteria. The strongest programs are run by people who combine ketamine-specific training with real mental-health treatment experience and enough emergency and addiction-medicine familiarity to handle the edge cases.

The physical setup has to match the clinical ambition: an appropriate, private, comfortable treatment space, monitoring capability, emergency equipment within reach, and staff trained to use it. And the practice needs the connective tissue that keeps quality consistent, meaning written protocols, tracked patient outcomes, systematic safety monitoring, continuing education, and access to peer consultation for the hard cases. None of this is exotic, but all of it is the difference between a real medical treatment and an unmonitored dose.

What This Costs and Who Can Get It

The economics of ketamine therapy are shaped by one fact: insurance mostly doesn't cover the generic form. Esketamine (Spravato) has a reimbursement path, and FDA-approved indications are the ones most likely to be covered, typically with prior authorization and its associated documentation and appeals. Racemic ketamine for psychiatric use is off-label, and most plans treat that as a coverage exclusion, so the majority of patients pay out of pocket. The direct costs are the medication, the clinician's time and expertise, and, for clinic-based routes, the monitoring and facility overhead, which is why IV and Spravato run more expensive per session than at-home sublingual. Against that sit benefits that are real but harder to line-item: fewer hospitalizations and emergency interventions, restored ability to work, better quality of life, and reduced overall healthcare utilization.

Access is genuinely uneven. Ketamine services concentrate in urban areas, leaving rural patients to travel, and the clinician workforce trained in this treatment is unevenly distributed. Cost is itself an access barrier for uninsured patients, compounded by the time the treatment takes, the need for a ride home after dosing, and the practical demands of scheduling around work and childcare. The reason an at-home telehealth model like ours exists is precisely to chip away at the geographic and cost sides of that problem: sublingual dosing supervised remotely removes the clinic overhead and the travel, which is a meaningful part of why it costs a fraction of an infusion course. It doesn't solve access on its own, but it widens the door.

The Bottom Line

Ketamine therapy is a meaningful addition to the options for patients with treatment-resistant conditions, not a replacement for what came before. Its glutamate-based mechanism, its rapid onset, and its maturing evidence base make it genuinely useful where standard approaches have fallen short. It is also not a cure and not right for everyone: careful patient selection, thorough screening, and disciplined monitoring are what separate good outcomes from bad ones, and integration with therapy and the rest of a treatment plan is what makes the benefits last.

For clinicians weighing whether to offer or refer for ketamine, the decision comes down to patient factors, your own expertise, your facility's capabilities, and the support systems around the treatment. For patients and families, the honest summary is this: for the specific population of people with treatment-resistant depression and related conditions who are appropriate candidates and who respond, the benefit can be substantial, sometimes life-changing, and it is worth understanding as a real option rather than a last resort or a miracle.

Refer a patient or get a curbside

For routine patient referrals, the eligibility screen below is the simplest path; we'll handle the evaluation and send you a summary. For clinician-to-clinician case discussion, the phone line is faster.

• Patient eligibility screen: tovanihealth.com/eligibility (5 minutes, FL, NJ, and CA residents)
• Clinician line: 561-468-6981 (curbside questions about a specific case welcome)
• What you get back: an evaluation summary with the treatment plan and any questions for your team.

Benjamin Soffer, DO, Tovani Health

Related reading: treatment-resistant depression, after failed antidepressants, the clinical evidence base, at-home vs. clinic comparison, what a session actually feels like.

Ready to begin? See how at-home ketamine therapy works or how to get a ketamine prescription online.